Drug (Dutasteride) intervention first for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prostate Cancer+1 MoreDrug (Dutasteride) intervention first - Drug
Eligibility
35 - 75
Male
What conditions do you have?
Select

Study Summary

This trial will test whether marine omega-3 fatty acids and 5-alpha-reductase inhibitors can help low-risk prostate cancer patients by slowing the progression of the disease.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 0-6-12 months

0-6-12 months
Determine the Clinical Utility of Urine-Based Cancer Markers in the Context of Interventions to Reduce Cancer Progression
Effect of Interventions on Gene Expression Profile
Effects of Interventions on Hormonal Metabolism
Effects of the Interventions on Lipid Metabolism From Blood and Prostatic Microenvironment

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Dietary intervention first
1 of 2
Drug intervention first
1 of 2

Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: Drug (Dutasteride) intervention first · No Placebo Group · N/A

Dietary intervention first
Other
Experimental Group · 1 Intervention: Dietary intervention first · Intervention Types: Other
Drug intervention first
Drug
Experimental Group · 1 Intervention: Drug (Dutasteride) intervention first · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 0-6-12 months

Who is running the clinical trial?

Prostate Cancer CanadaOTHER
9 Previous Clinical Trials
7,538 Total Patients Enrolled
7 Trials studying Prostate Cancer
7,414 Patients Enrolled for Prostate Cancer
CHU de Quebec-Universite LavalLead Sponsor
152 Previous Clinical Trials
101,347 Total Patients Enrolled
9 Trials studying Prostate Cancer
2,457 Patients Enrolled for Prostate Cancer
Vincent Fradet, MDPrincipal InvestigatorLaval University

Eligibility Criteria

Age 35 - 75 · Male Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: